Neoplasm Metastasis
Conditions
Keywords
Brain, metastases
Brief summary
This study is to look more closely at the tumor removed during your surgery, and to follow your condition after your treatment. The purpose of this study is to determine what side effects are common or more rare from this treatment, how well the treatment has worked for you, and to track whether you develop other brain metastases.
Interventions
RADIATIONNovalis Shaped Beam Surgery
Treatment using Novalis SRS
Sponsors
University of Rochester
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have a previously histopathologically proven diagnosis of malignancy. * Patients must be evaluated by Neurosurgery and Radiation Oncology * Patients must have 1-3 brain metastases seen on MRI or CT imaging. At least one brain metastases must be considered resectable by craniotomy as determined by the treating neurosurgeon. Brain lesion resection must be considered standard of care. A not uncommon situation is for a patient to undergo resection of a solitary metastasis, but prove to have more lesions on subsequent MRIs (perhaps too small to be seen on a pre-operative MRI). These patients will be eligible if the total number of lesions is 1-3. * All lesions must be treatable by SRS as determined by the treating neurosurgeon and radiation oncologist. * All lesions must be \<4 cm in greatest dimension. For patients with more than 1 brain metastases, only 1 lesion can exceed 3 cm in greatest dimension. * In patients treated to the post-op surgical cavity, this cavity must be encompassed by a CTV of \<5 cm. * Patients must have a Karnofsky performance status ≥60. * Extracranial disease must not be considered imminently life threatening (\<2 month anticipated survival from extracranial disease). * Patients must be informed of the investigational nature of this study and must sign and give written informed consent in accordance with institutional and federal guidelines.
Exclusion criteria
* KPS\<60 * life expectancy \> 2 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determine toxicity of treatment with cranial SRS and resection | During treatment and long term follow-up |
| Determine the local control of the treated lesion(s), distant brain control and overall patient survival. | During treatment and long term follow-up |
Secondary
| Measure | Time frame |
|---|---|
| Tissue from the resected brain metastases will be evaluated with immunohistochemistry and/or comparative genomic hybridization to assess for potential markers for clinical outcome as well as potential markers of radiation response. | Following surgical resection |
Countries
United States
Outcome results
None listed